Nightingale Health Oyj 관리

관리 기준 확인 2/4

Nightingale Health Oyj CEO는 Teemu Suna, Jan2014 에 임명되었습니다 의 임기는 10.83 년입니다. 총 연간 보상은 € 1.68M, 17.3% 로 구성됩니다. 17.3% 급여 및 82.7% 보너스(회사 주식 및 옵션 포함). 는 € 7.37M 가치에 해당하는 회사 주식의 4.42% 직접 소유합니다. 7.37M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 6.8 년입니다.

주요 정보

Teemu Suna

최고 경영자

€1.7m

총 보상

CEO 급여 비율	17.3%
CEO 임기	10.8yrs
CEO 소유권	4.4%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

May 03

CEO 보상 분석

Teemu Suna 의 보수는 Nightingale Health Oyj 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	€2m	€291k	-€17m
Mar 31 2024	n/a	n/a	-€18m
Dec 31 2023	n/a	n/a	-€18m
Sep 30 2023	n/a	n/a	-€18m
Jun 30 2023	€2m	€299k	-€18m
Mar 31 2023	n/a	n/a	-€18m
Dec 31 2022	n/a	n/a	-€19m
Sep 30 2022	n/a	n/a	-€17m
Jun 30 2022	€2m	€290k	-€16m
Mar 31 2022	n/a	n/a	-€14m
Dec 31 2021	n/a	n/a	-€12m
Sep 30 2021	n/a	n/a	-€11m
Jun 30 2021	€776k	€287k	-€10m

보상 대 시장: Teemu 의 총 보상 ($USD 1.75M )은 Finnish 시장( $USD 597.96K ).

보상과 수익: 회사가 수익성이 없는 동안 Teemu 의 보상이 증가했습니다.

CEO

Teemu Suna (42 yo)

10.8yrs

테뉴어

€1,684,000

보상

Mr. Teemu Suna is Founder at Nightingale Health Ltd. and has been its Chief Executive Officer since 2014. He is also Director at Nightingale Health Ltd.since 2021. His main work experience: Fujitsu Servic...

리더십 팀

이름	위치	테뉴어	보상	소유권
Teemu Suna	Founder	10.8yrs	€1.68m	4.42% € 7.4m
Antti Kangas	Founder	11.8yrs	€24.00k	8.88% € 14.8m
Satu Saksman	Co-Founder & COO	9.8yrs	데이터 없음	1.03% € 1.7m
Peter Wurtz	Founder & Scientific Director	no data	데이터 없음	1.89% € 3.2m
Pasi Soininen	Founder & Laboratory Director	no data	데이터 없음	8.88% € 14.8m
Tuukka Paavola	Chief Financial Officer	2.9yrs	데이터 없음	0.012% € 20.7k
Jeffrey Barrett	Chief Scientific Officer	3.2yrs	데이터 없음	0.014% € 23.1k
Minja Salmio	Chief Legal Officer	7.8yrs	데이터 없음	0.14% € 228.5k
Salla Ruosaari	Chief Research & Development Officer	3.8yrs	데이터 없음	0.12% € 207.7k
Charles Alessi	Chief Medical Officer	no data	데이터 없음	데이터 없음
Laura Pulkkinen	Director of Business Operations	no data	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

43yo

평균 연령

경험이 풍부한 관리: HEALTH 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Teemu Suna	Founder	8.8yrs	€1.68m	4.42% € 7.4m
Antti Kangas	Founder	11.8yrs	€24.00k	8.88% € 14.8m
Timo Soininen	Independent Director	4.8yrs	€24.00k	0.95% € 1.6m
Leena Niemisto	Independent Chairman	3.8yrs	€24.00k	데이터 없음
Ilkka Laurila	Independent Director	1.6yrs	€24.00k	0.027% € 44.2k
Olli Karhi	Independent Director	9.8yrs	€24.00k	데이터 없음
George Smith	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
John Danesh	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Eline Slagboom	Members of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jose Ordovas	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: HEALTH 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Nightingale Health Oyj 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Nightingale Health Appoints Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK

Nightingale Health Oyj, Annual General Meeting, Nov 08, 2024

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Nightingale Health Appoints Maximilian LeRoux as Chief Commercial Officer, Effective August 1, 2023

Recent updates

Nightingale Health Appoints Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK

Consensus revenue estimates fall by 25%

Nightingale Health Oyj, Annual General Meeting, Nov 08, 2024

Full year 2024 earnings: Revenues miss analyst expectations

Nightingale Health Receives Third Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore

Nightingale Health Attains UKCA Marking for its Blood Analysis Technology to Bring Its Technology to Healthcare Use in the United Kingdom

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to €0.27 loss, revenue downgraded

Nightingale Health Oyj to Report First Half, 2024 Results on Mar 07, 2024

Nightingale Health Oyj Receives Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore

Nightingale Health plc Receives Five New Patents for Its Proprietary Health Risk Detection Capability

Nightingale Health Completes the Analysis of All 500,000 UK Biobank Samples Creating the Largest Blood Biomarker Database for Chronic Disease Research and Prevention

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Full year 2023 earnings: Revenues miss analyst expectations

Nightingale Health Receives Three New Patents Further Strengthening Its IP Portfolio

Nightingale Health Rolls Out Remote Blood Collection Kit for Medical Research and Clinical Trials

Nightingale Health plc Announces Population Study Combining Blood Biomarkers and Genetics Demonstrates

Nightingale Health plc Announces Biomarker Results of Additional 200,000 Blood Samples Soon Available to Researchers Globally

Nightingale Health Oyj to Report Fiscal Year 2023 Results on Sep 28, 2023

Nightingale Health Receives Six Patent Approvals for Its Proprietary Health Risk Detection Platform

Nightingale Health Appoints Maximilian LeRoux as Chief Commercial Officer, Effective August 1, 2023

First half 2023 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 48%, EPS downgraded

Nightingale Health Oyj to Report First Half, 2023 Results on Mar 23, 2023

Price target decreased to €1.40

Full year 2022 earnings: Revenues miss analyst expectations

Nightingale Health Oyj to Report Q4, 2022 Results on Oct 27, 2022

Nightingale Health Oyj to Report First Half, 2023 Results on Mar 02, 2023

Price target decreased to €4.00

Nightingale Health Launches Consumer Service Livit by Nightingale Health Utilizing Its At-Home Testing Solution

Consensus forecasts updated

Nightingale Health Oyj to Report Q2, 2022 Results on Feb 24, 2022

Nightingale Health Oyj (HLSE:HEALTH) completed the acquisition of Negen Oy.

Nightingale Health Oyj (HLSE:HEALTH) agreed to acquire Negen Ltd.

Full year 2021 earnings released: €0.27 loss per share (vs €0.085 loss in FY 2020)

Nightingale Health Oyj Successfully Completes the First Phase of Its At-Home Blood Testing Pilot

Chief Product Officer has left the company

Nightingale Health Oyj has completed an IPO in the amount of €137.499998 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령